Market closed
Silverback Therapeutics/$SPRY
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Silverback Therapeutics
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Ticker
$SPRY
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
26
Website
SPRY Metrics
BasicAdvanced
$1.1B
Market cap
-
P/E ratio
-$0.51
EPS
1.00
Beta
-
Dividend rate
Price and volume
Market cap
$1.1B
Beta
1
52-week high
$16.89
52-week low
$5.02
Average daily volume
1.3M
Financial strength
Current ratio
12.56
Quick ratio
12.396
Total debt to equity
0.051
Management effectiveness
Return on assets (TTM)
-16.22%
Return on equity (TTM)
-22.41%
Valuation
Price to revenue (TTM)
420.649
Price to book
5.4
Price to tangible book (TTM)
5.61
Price to free cash flow (TTM)
-23.467
Growth
Revenue change (TTM)
8,460.00%
Earnings per share change (TTM)
-27.26%
What the Analysts think about SPRY
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Silverback Therapeutics stock.
SPRY Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SPRY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SPRY News
AllArticlesVideos
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
GlobeNewsWire·3 days ago
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
GlobeNewsWire·1 week ago
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Silverback Therapeutics stock?
Silverback Therapeutics (SPRY) has a market cap of $1.1B as of December 22, 2024.
What is the P/E ratio for Silverback Therapeutics stock?
The price to earnings (P/E) ratio for Silverback Therapeutics (SPRY) stock is 0 as of December 22, 2024.
Does Silverback Therapeutics stock pay dividends?
No, Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders as of December 22, 2024.
When is the next Silverback Therapeutics dividend payment date?
Silverback Therapeutics (SPRY) stock does not pay dividends to its shareholders.
What is the beta indicator for Silverback Therapeutics?
Silverback Therapeutics (SPRY) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.